%0 Journal Article
%A Perez-Belmonte, Luis M
%A Sanz-Canovas, Jaime
%A Garcia-de-Lucas, Maria D
%A Ricci, Michele
%A Aviles-Bueno, Beatriz
%A Cobos-Palacios, Lidia
%A Perez-Velasco, Miguel A
%A Lopez-Sampalo, Almudena
%A Bernal-Lopez, M Rosa
%A Jansen-Chaparro, Sergio
%A Miramontes-Gonzalez, Jose P
%A Gomez-Huelgas, Ricardo
%T Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
%D 2022
%@ 1664-2392
%U http://hdl.handle.net/10668/20560
%X The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.
%K Health status
%K Heart failure
%K Obesity
%K Semaglutide
%K Type 2 diabetes
%~